Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause